Shanghai Rendu Biotechnology Co. Ltd. A - Asset Resilience Ratio

Latest as of March 2026: 70.50%

Shanghai Rendu Biotechnology Co. Ltd. A (688193) has an Asset Resilience Ratio of 70.50% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Shanghai Rendu Biotechnology Co. Ltd. A's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥693.75 Million
≈ $101.52 Million USD Cash + Short-term Investments

Total Assets

CN¥984.02 Million
≈ $143.99 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Shanghai Rendu Biotechnology Co. Ltd. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 688193 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Rendu Biotechnology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688193 total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥693.75 Million 70.5%
Total Liquid Assets CN¥693.75 Million 70.50%

Asset Resilience Insights

  • Very High Liquidity: Shanghai Rendu Biotechnology Co. Ltd. A maintains exceptional liquid asset reserves at 70.50% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Rendu Biotechnology Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Shanghai Rendu Biotechnology Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Prostatype Genomics AB
ST:PROGEN
Diagnostics & Research -10.72%
Proteome Sciences PLC
LSE:PRM
Diagnostics & Research 19.84%
ProPhase Labs Inc
NASDAQ:PRPH
Diagnostics & Research 0.00%
Eurofins Scientific SE
PA:ERF
Diagnostics & Research 7.20%
SenzaGen AB
ST:SENZA
Diagnostics & Research 29.75%
Diagnósticos da América S.A
SA:DASA3
Diagnostics & Research 10.42%
Cryosite Ltd
AU:CTE
Diagnostics & Research 5.65%
Avricore Health Inc
V:AVCR
Diagnostics & Research 1.71%

Annual Asset Resilience Ratio for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Rendu Biotechnology Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 70.04% CN¥693.47 Million
≈ $101.48 Million
CN¥990.17 Million
≈ $144.89 Million
+18.65pp
2024-12-31 51.39% CN¥510.96 Million
≈ $74.77 Million
CN¥994.36 Million
≈ $145.51 Million
+46.63pp
2023-12-31 4.76% CN¥50.21 Million
≈ $7.35 Million
CN¥1.05 Billion
≈ $154.34 Million
-44.01pp
2022-12-31 48.77% CN¥530.98 Million
≈ $77.70 Million
CN¥1.09 Billion
≈ $159.31 Million
+31.60pp
2019-12-31 17.17% CN¥32.12 Million
≈ $4.70 Million
CN¥187.07 Million
≈ $27.37 Million
--
pp = percentage points

About Shanghai Rendu Biotechnology Co. Ltd. A

SHG:688193 China Diagnostics & Research
Market Cap
$267.08 Million
CN¥1.83 Billion CNY
Market Cap Rank
#15478 Global
#4551 in China
Share Price
CN¥45.55
Change (1 day)
+0.82%
52-Week Range
CN¥40.38 - CN¥61.67
All Time High
CN¥63.91
About

Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more